Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of “Hold” by Brokerages

by · The Markets Daily

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) have earned a consensus rating of “Hold” from the five analysts that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $2.50.

HRTX has been the subject of a number of recent analyst reports. Needham & Company LLC downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Zacks Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. HC Wainwright reduced their price objective on Heron Therapeutics to $2.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Tuesday, April 21st. Finally, Wall Street Zen downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Get Our Latest Stock Report on Heron Therapeutics

Heron Therapeutics Trading Down 5.5%

NASDAQ HRTX opened at $0.38 on Wednesday. The firm has a market capitalization of $72.30 million, a P/E ratio of -2.12 and a beta of 1.58. The company has a current ratio of 2.53, a quick ratio of 1.51 and a debt-to-equity ratio of 17.51. The business has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $1.07. Heron Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.30.

Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). The business had revenue of $34.71 million during the quarter, compared to the consensus estimate of $36.72 million. Heron Therapeutics had a negative net margin of 20.53% and a negative return on equity of 7,747.30%. On average, analysts predict that Heron Therapeutics will post -0.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC grew its stake in shares of Heron Therapeutics by 39.1% during the 4th quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 6,858 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Heron Therapeutics by 5.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock worth $499,000 after acquiring an additional 11,716 shares during the period. B. Riley Wealth Advisors Inc. bought a new position in shares of Heron Therapeutics during the 2nd quarter worth $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Heron Therapeutics by 19.3% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,756 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 13,544 shares during the period. Finally, Orchard Capital Management LLC grew its stake in shares of Heron Therapeutics by 2.6% during the 3rd quarter. Orchard Capital Management LLC now owns 677,290 shares of the biotechnology company’s stock worth $853,000 after acquiring an additional 17,357 shares during the period. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

(Get Free Report)

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.

Featured Stories